Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors

NCT06736704 is registered in ClinicalTrials.gov with Pikavation Therapeutics, Inc. as lead sponsor.

NCT NCT06736704
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06736704 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2, Open-Label Dose Escalation and Expansion Study of SNV4818 as Monotherapy or in Combination With Other Anticancer Agents in Participants With Advanced Solid Tumors
Lead sponsor
Pikavation Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 20, 2025
Completion date
June 30, 2027
Enrollment
320 (estimated)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors